Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 398 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: hemoglobin A1c Clear all

Conditions: Type 2 Diabetes
Interventions: Sitagliptin, Basal Bolus, Metformin and Sitagliptin, Glargine, Glargine 50%, Glargine 80%; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 5
States / cities: Atlanta, Georgia • Ann Arbor, Michigan • Columbus, Ohio + 1 more

Conditions: Diabetes
Interventions: Phase II of the Study: Information regarding Current Diabetes Control; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Obesity, Insulin Resistance, Metabolically Healthy Obesity, Obesity, Metabolically Benign
Interventions: People with Metabolically Unhealthy Obesity - Low Calorie Diet; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 25 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Type 2 Diabetes Mellitus (T2DM)
Interventions: ALN-KHK, Placebo; Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 11
States / cities: Phoenix, Arizona • Vista, California • Lake Worth, Florida + 8 more

Conditions: Diabetes Mellitus, Hypertension, Hyperlipidemia
Interventions: Pre-filled trays; Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Type 2 Diabetes
Interventions: SMBG to guide clinical decisions, SMBG and CGM; Other
Lead sponsor: HealthPartners Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: pioglitazone, inhaled human insulin; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 110
States / cities: Ozark, Alabama • Tuscaloosa, Alabama • Vestavia Hills, Alabama + 100 more

Conditions: Diabetes Mellitus, Type 2
Interventions: vildagliptin + metformin, metformin; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 78 Years
Enrollment: 317 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 16
States / cities: Pine Bluff, Arkansas • Long Beach, California • Denver, Colorado + 11 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Usual Care, Intensive Behavioral Intervention, Monthly Screening for Risk; Other · Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 21 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Chelsea, Michigan

Conditions: Insulin Resistance, Type 2 Diabetes, Obesity & Overweight, Healthy Adult Participants
Interventions: Alpelisib 300 mg, Alpelisib Challenge Test (ACT): Mixed Meal Tolerance Test (MMTT) after taking alpelisib, Hyperglycemic clamp; Drug · Diagnostic Test
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV, Diabetes, Hyperglycemia
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: Stress Hyperglycemia, Diabetes Mellitus Type 2
Interventions: Not listed
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: New Haven, Connecticut • Norwalk, Connecticut

Conditions: Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions: Diabetes Self-Management Training (DSMT), Remote Glucose Monitoring (RGM), Community Health Worker tailored support; Behavioral
Lead sponsor: Sinai Health System; Other
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Prediabetes
Interventions: Blood Test Group Intervention, Brochure Group Intervention; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 75 Years
Enrollment: 315 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Diabetes Mellitus, Type 2
Interventions: Continuous Glucose Monitor, Usual Care; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Diabetes Mellitus, Type 2
Interventions: Canagliflozin, Placebo, Metformin, Sulphonylruea; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 469 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 37
States / cities: Huntsville, Alabama • Little Rock, Alaska • Phoenix, Arizona + 34 more

Conditions: Diabetes Mellitus
Interventions: Not listed
Lead sponsor: David Grant U.S. Air Force Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Travis Air Force Base, California

Conditions: Diabetes
Interventions: Application Validation; Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Healthy Volunteers
Interventions: Placebo, Canagliflozin; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetes
Interventions: Not listed
Lead sponsor: Asahi Kasei Therapeutics Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 8
States / cities: Los Angeles, California • Lexington, Kentucky • New Orleans, Louisiana + 4 more

Conditions: Coronary Artery Disease
Interventions: Medical/Behavioral therapy, Standard of Care, Registry; Other
Lead sponsor: Emory University; Other
Eligibility: 21 Years to 90 Years
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 5
States / cities: Atlanta, Georgia

Conditions: Diabetes Mellitus, Type 2
Interventions: GSK189075, pioglitazone, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 14
States / cities: Mesa, Arizona • Hollywood, Florida • Miami, Florida + 9 more

Conditions: Insulin Resistance, Hyperinsulinemia, Obesity, Healthy
Interventions: Insulin regular, 2.0-3.2 mU/m2/min (euinsulinemia), Insulin regular, 32 mU/m2/min (hyperinsulinemia), Octreotide Acetate, 6-45 ng/kg/min, Dextrose 20 % in Water, Glucagon, 0-0.5 ng/kg/min; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Type1 Diabetes Mellitus, Diabetes Mellitus, Type 1, Autoimmune Diabetes, Juvenile Diabetes, Diabetes Mellitus Complication, Diabetic Nephropathies, Metabolic Disease, Diabetic Kidney Disease
Interventions: Blood draw, Urine sample collection, DXA scan; Diagnostic Test
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 7 Years to 18 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Search by objective public record fields.

Sitagliptin Therapy in Hospitalized Patients With Type 2 Diabetes

Using Patient Feedback to Improve Communication Regarding Glycemic Control to Patients With Diabetes

Small Extracellular Vesicles and Insulin Action

A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM

Effects of Use of a Connected Pillbox On Medication Adherence

Modal Day Analysis of Self Monitoring Blood Glucose Versus Continuous Glucose Monitoring

Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes

Efficacy and Safety of Fixed Combination Therapy of Vildagliptin and Metformin (25/1000 mg Bid) in Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy (HbA1c 7.0-9.5%)

Quality Initiative to Improve Glucose Control in Type 2 Diabetic Patients

Alpelisib Challenge Test (ACT)

Accuracy of Hemoglobin A1C to Predict Glycemia in HIV

Study of Stress Hyperglycemia as an Indicator of Diabetes Mellitus

Improving Diabetes Equity and Advancing Care Study

ForgIng New Paths to Prevent DIabeTes (FINDIT)

Addressing Disparities in Diabetes Care

The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea)

Evaluating the Effects of EECP on Circulation, Blood Glucose Level and Blood Pressure in Type 2 Diabetes Mellitus

Validation of the Diabetes Deep Neural Network Score for Diabetes Mellitus Screening

Acute Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor on Bone Metabolism in Healthy Volunteers

Lucica ® Glycated Albumin-L Clinical Program - Pivotal Study

The Precision CAD Trial

Dose-Ranging Study in Treatment Naive Type 2 Diabetes Mellitus(T2DM)

Graded Insulin Suppression Test P&F

MEtabolic and Renal Effects of AutoMAted Insulin Delivery Systems in Youth With Type 1 Diabetes Mellitus